NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today reported its financial results for the three months ended June 30, 2011, and provided an update on the Company’s activities in the second quarter.
